|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications显示文摘Nanomaterials are advancing in several directions with significant progress being achieved with respect to their synthesis, functionalization and biomedical application. In this review, we will describe several classes of prototypical nanocarriers, such as liposomes, silicon particles, and gold nanoshells, in terms of their individual function as well as their synergistic use. Active and passive targeting, photothermal ablation, and drug controlled release constitute some of the crucial functions identified to achieve a medical purpose. Current limitations in targeting, slow clearance, and systemic as well as local toxicity are addressed in reference to the recent studies that attempted to comprehend and solve these issues. The demand for a more sophisticated understanding of the impact of nanomaterials on the body and of their potential immune response underlies this discussion. Combined components are then discussed in the setting of multifunctional nanocarriers, a class of drug delivery systems we envisioned, proposed, and evolved in the last 5 years. In particular, our third generation of nanocarriers, the multistage vectors, usher in the new field of nanomedicine by combining several components onto multifunctional nanocarriers characterized by emerging properties and able to achieve synergistic effects. | MARTINEZ Jonathan O BROWN Brandon S QUATTROCCHI Nicoletta EVANGELOPOULOS Michael FERRARI Mauro TASCIOTTI Ennio | 2012 | Chinese Science Bulletin2012，57，31： | 4 |
| 2 | Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil显示文摘BACKGROUND Inflammatory bowel diseases(IBD)have been associated with a low quality of life(QoL)and a negative impact on work productivity compared to the general population.Information about disease control,patient-reported outcomes(PROs),treatment patterns and use of healthcare resources is relevant to optimizing IBD management.AIM To describe QoL and work productivity and activity impairment(WPAI),treatment patterns and use of healthcare resources among IBD patients in Brazil.METHODS A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn’s disease(CD)or ulcerative colitis(UC).At enrolment,active CD and UC were defined as having a Harvey Bradshaw Index≥8 or a CD Activity Index≥220 or calprotectin>200μg/g or previous colonoscopy results suggestive of inadequate control(per investigator criteria)and a 9-point partial Mayo score≥5,respectively.The PRO assessment included the QoL questionnaires SF-36 and EQ-5D-5L,the Inflammatory Bowel Disease Questionnaire(IBDQ),and the WPAI questionnaire.Information about healthcare resources and treatment during the previous 3 years was collected from medical records.Chi-square,Fisher’s exact and Student’s t-/Mann-Whitney U tests were used to compare PROs,treatment patterns and the use of healthcare resources by disease activity(α=0.05).RESULTS Of the 407 patients in this study(CD/UC:64.9%/35.1%,mean age 42.9/45.9 years,54.2%/56.6%female,38.3%/37.1%employed),44.7%/25.2%presented moderate-to-severe CD/UC activity,respectively,at baseline.Expressed in median values for CD/UC,respectively,the SF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2,the EQ-visual analog scale score was 80.0/70.0,and the IBDQ overall score was 164.0/165.0.Moderate to severe activity,female gender,being unemployed,a lower educational level and lower income were associated with lower QoL(P<0.05).Median work productivity impairment was 20%and 5%for CD and UC patients,respectively,and activity impairment was 30%,the latter being higher among patients with moderate to severe disease activity compared to patients with mild or no disease activity(75.0%vs 10.0%,P<0.001).For CD/UC patients,respectively,25.4%/2.8%had at least one surgery,38.3%/19.6%were hospitalized,and 70.7%/77.6%changed IBD treatment at least once during the last 3 years.The most common treatments at baseline were biologics(75.3%)and immunosuppressants(70.9%)for CD patients and 5-ASA compounds(77.5%)for UC patients.CONCLUSION Moderate to severe IBD activity,especially among CD patients,is associated with a substantial impact on QoL,work productivity impairment and an increased number of IBD surgeries and hospitalizations in Brazil. | Rogerio Serafim Parra Julio MF Chebli Heda MBS Amarante Cristina Flores Jose ML Parente Odery Ramos Milene Fernandes Jose JR Rocha Marley R Feitosa Omar Feres Antonio S Scotton Rodrigo B Nones Murilo M Lima Cyrla Zaltman Carolina D Goncalves Isabella M Guimaraes Genoile O Santana Ligia Y Sassaki Rogerio S Hossne Mauro Bafutto Roberto LK Junior Mikaell AG Faria Sender J Miszputen Tarcia NF Gomes Wilson R Catapani Anderson A Faria Stella CS Souza Rosana F Caratin Juliana T Senra Maria LA Ferrari | 2019 | World Journal of Gastroenterology2019，25，38： | 2 |
| 3 | Electron transfer in a new highly conducting donor-acceptor complex显示文摘 | Ferraris J P Cowan D O Walatka V | 1973 | J Am Chem Soc1973，95，： | 2 |
| 4 | Ammoniavariations in phyto-treatment ponds of land-based fish farmwastewater显示文摘 | PORRELL O FERRARI G LENZI M | 2003 | Aquaculture2003，219，： | 1 |
| 5 | Prospective Study of Hyperglycemia and Cancer Risk显示文摘 | Stattin P Bjor O Ferrari P | 2007 | Diabetes Care2007，30，3： | 1 |
| 6 | Analysis of shoterm oscillations of R-R and arterial pressure in conscious dogs 显示文摘 | Rimoldi O Pierini S Ferrary A | 1990 | Am J Physiol1990，258，4： | 1 |
| 7 | Unanswered ques- tions for management of acute eoronary syndrome: risk stratifi- cation of patients with minimal disease or normal findings on coronary angiography 显示文摘 | Bugiardini R Manfrini O De Ferrari GM | 2006 | Arch Intern Med2006，166，13： | 1 |
| 8 | Preva- the United States, UnitedKingdom, and Australia : Arousal and avoidance de- lays among adults 显示文摘 | Ferrari J R O Callaghan lence of procrastination in J & Newbegin I | 2005 | North American Journal of Psychology2005，，： | 1 |
| 9 | Sex determination of the pseudo XO/XX type in the Brazilian lizard Polychrus species(Sauria,Iguanidae)显示文摘 | Peccinini-Seale D Frota-Pessoa O Ferrari I | | 0，，： | 1 |
| 10 | Prospective study of hyperglycemia and cancer risk显示文摘 | Stattin P Bjor O Ferrari P | 2007 | Diabetes Care2007，30，3： | 1 |
| 11 | An 'alternative plate tec- tonic model for the Palaeozoic-Early Mesozoic Palaeotethyan evolution of Southeast Asia (Northern Thailand-Bumla) 显示文摘 | Ferrari O M Hochard C Stampfli G M | 2008 | Tectonophysies2008，451，： | 1 |
| 12 | Electron transfer in a new highly conducting donor-acceptor complex显示文摘 | Ferraris J Cowan D O Waltka V | 1973 | J Am Chem Soc1973，95，3： | 1 |
| 13 | Molecular conductors derived from bis-dis-dithiolate metal complexes显示文摘 | Ferraris J P Cow am D O Walaka J V | 1973 | J Am soc1973，95，： | 1 |
| 14 | Eleetron transfer in a new highly conducting donor-acceptor complex显示文摘 | Ferraris J P Cowan D O Walatka V | 1973 | J Am Chem Soc1973，95，： | 1 |
| 15 | T Cell Assays and MIATA: The Essential Minimum for Maximum Impact显示文摘 | C.M. Britten S. Janetzki L.H. Butterfield G. Ferrari C. Gouttefangeas C. Huber M. Kalos H.I. Levitsky H.T. Maecker C.J.M. Melief J. O’Donnell-Tormey K. Odunsi L.J. Old T.H.M. Ottenhoff C. Ottensmeier G. Pawelec M. Roederer B.O. Roep P. Romero S.H. van der | 2012 | Immunity2012，，1： | 1 |
| 16 | Prospective study of hyper-glycemla and cancer risk 显示文摘 | Stilttin P Bjor O Ferrari P | 2007 | Diabetes Care2007，30，3： | 1 |
| 17 | Use of the DNA Flow-Thru Chip,a three dimensional biochip,for typing and subtyping ofnfluenza virus显示文摘 | Kessler N Ferraris O Palmer K | 2004 | J Clin Microbiol2004，42，： | 1 |
| 18 | Role of Drpl, a key mitochondrial fission protein, in neuropathic pain 显示文摘 | Ferrari LF Chum A Bogen O | 2011 | J Neurosci2011，31，11： | 1 |
| 19 | Prospective study of hyperglycemia and cancer risk显示文摘 | STATTIN P BJOR O FERRARI P | 2007 | Diabetes Care2007，30，3： | 1 |
| 20 | Serum concentration of NSE and S-100b during LVAD in nonresuscitated patients显示文摘 | Pfeifer R Ferrari M B(o)rner A | | 0，，01： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员